Evaluation of the pre-posterior distribution of optimized sampling times for the design of pharmacokinetic studies

Journal of Biopharmaceutical Statistics

Volumn 22, Issue 1, 2012, Pages 16-29

  Duffull, Stephen B ^a   Graham, Gordon ^b   Mengersen, Kerrie ^c   Eccleston, John ^d  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NOVARTIS PHARMA AG   (Switzerland)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adaptive design; D optimal design; MCMC; Pharmacokinetics

Indexed keywords

ARTICLE; BAYES THEOREM; COMPARTMENT MODEL; METHODOLOGY; MONTE CARLO METHOD; PHARMACOKINETICS; PRIORITY JOURNAL; PROBABILITY; SAMPLING; SAMPLING TIME; STATISTICAL DISTRIBUTION; STATISTICAL PARAMETERS; SYSTEMATIC ERROR; THEORETICAL MODEL; TIME;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; STATISTICAL DISTRIBUTIONS; TIME FACTORS;

EID: 84856295580     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2010.500065     Document Type: Article

References (22)

1. Atkinson, A. C., Donev, D. N. (1992). Optimum Experimental Designs. Oxford: Oxford University Press.
2. Bogacka, B., Patan, M. (2006). Efficient sampling windows for parameter estimation in population models. PAGE 15. abstr. 963. Available at www.page-meeting.org/?abstract=963
3. Chaloner, K., Verdinelli, I. (1995). Bayesian experimental design: a review. Statistical Science 10: 273-304.
4. Chenel, M., Ogungbenro, K., Duval, V., Laveille, C., Jochemsen, R., Aarons, L. (2005). Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial. Journal of Pharmacokinetics and Pharmacodynamics 32 (5-6): 737-756. (Pubitemid 41772355)
5. D'Argenio, D. Z. (1981). Optimal sampling times for pharmacokinetic experiments. Journal of Pharmacokinetics and Biopharmaceutics 9: 739-756. (Pubitemid 12184821)
6. D'Argenio, D. Z. (1990). Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Mathematical Biosciences 99: 105-118. (Pubitemid 20286284)
7. Dodds, M. G., Hooker, A. C., Vicini, P. (2005). Robust population pharmacokinetic experiment design. Journal of Pharmacokinetics and Pharmacodynamics 32: 33-64. (Pubitemid 41586840)
8. Duffull, S. B., Mentré, F., Aarons, L. (2001). Optimal design of a population pharmacodynamic experiment for ivabradine. Pharmeutical Research 18 (1): 83-89. (Pubitemid 32299626)
9. Duffull, S. B., Waterhouse, T. H., Eccleston, J. A. (2005). Some considerations on the design of population pharmacokinetic studies. Journal of Pharmacokinetics and Pharmacodynamics 32: 441-457.
10. Graham, G., Aarons, L. (2006). Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments. Statistics in Medicine 25 (23): 4004-4019. (Pubitemid 44823871)
11. Green, G., Duffull, S. B. (2003). Prospective evaluation of a D-optimal designed population pharmacokinetic study. Journal of Pharmacokinetics and Pharmacodynamics 30 (2): 145-161. (Pubitemid 36886574)
12. Gueorguieva, I., Aarons, L., Ogungbenro, K., Jorga, K. M., Rodgers, T., Rowland, M. (2006). Optimal design for multivariate response pharmacokinetic models. Journal of Pharmacokinetics and Pharmacodynamics 33: 97-124.
13. Hooker, A., Vicini, P. (2005). Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments. AAPS Journal 7 (4): E759-785.
14. McGree, J. M., Eccleston, J. A., Duffull, S. B. (2008). Compound optimal design criteria for nonlinear models. Journal of Biopharmaceutical Statistics 18: 646-661. (Pubitemid 351951538)
15. Mentré, F., Mallet, A., Baccar, D. (1997). Optimal design in random-effects regression models. Biometrika 84: 429-442.
16. Ogungbenro, K., Aarons, L. (2007). Design of population pharmacokinetic experiments using prior information. Xenobiotica 37 (10-11): 1311-1330. (Pubitemid 350035531)
17. Ogungbenro, K., Gueorguieva, I., Majid, O., Graham, G., Aarons, L. (2007). Optimal design for multiresponse pharmacokinetic-pharmacodynamic modelsDealing with unbalanced designs. Journal of Pharmacokinetics and Pharmacodynamics 34 (3): 313-331. (Pubitemid 46873029)
18. Retout, S., Mentré, F. (2003). Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. Journal of Biopharmaceutical Statistics 13: 209-227. (Pubitemid 36523158)
19. Robert, C., Casella, G. (2004). Monte Carlo Statistical Methods. New York: Springer Science and Business Media.
20. Tod, M., Rocchisani, J. M. (1997). Comparison of ED, EID and API criteria for the robust optimization of sampling times in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 25: 515-537. (Pubitemid 28186450)
21. Walter, E., Pronzato, L. (1987). Optimal experiment design for nonlinear models subject to large prior uncertainties. American Journal of Physiology 253: R530-R534.
22. Waterhouse, T. H., Redman, S., Duffull, S. B., Eccleston, J. A. (2005). Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics 32 (3-4): 521-545. (Pubitemid 41738439)